Topical Cetirizine in Androgenetic Alopecia in Females
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist,
widely used in daily practice. A study showed that cetirizine causes a significant reduction
in both the inflammatory cell infiltrate and PGD2 production. A pilot study on topical
cetirizine showed that cetirizine increased total hair density, terminal hair density and
diameter. Also, its lower potential side effects if compared with other drugs commonly used
for AGA, as minoxidil, can promote a wider use and better compliance of cetirizine in the
future for the treatment of AGA. Combinations of therapies are likely to be more efficacious
than single treatments.
Treatments to clinically improve scalp hair density and reduce mid-pattern thinning leading
to improved scalp coverage are highly important for the affected women. On the basis of the
above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA
treatment, the aim of this study is to evaluate the efficacy and tolerability of topical
cetirizine in female patients with AGA.